Notice for tolebrutinib (Sanofi-Aventis Australia Pty Ltd)
Active ingredients
tolebrutinib
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
Treatment of non-relapsing secondary progressive multiple sclerosis (nrSPMS) and to slow disability accumulation independent of relapse activity in adults
Therapeutic area
Neurology